28. They both would have liked to see how well this vaccine would have held up against Omicron. The data Novavax is presenting are from a trial that ended last fall. But both said their understanding of #VRBPAC's job is to assess the data they've seen & leave the decision to FDA.

— Helen Branswell 🇨🇦 (@HelenBranswell) June 7, 2022